Pinometostat

DRUG2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Acute Myeloid LeukemiaAcute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLLLeukemia CutisRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Phase 1

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

CompletedNCT03701295

National Cancer Institute (NCI)Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL, Leukemia Cutis, Recurrent Acute Myeloid Leukemia +1

Start: 2020-03-06End: 2021-01-12Updated: 2023-10-18

Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement

TerminatedNCT03724084

National Cancer Institute (NCI)Acute Myeloid Leukemia

Start: 2019-04-10End: 2022-11-14Updated: 2025-06-18

Related Papers

A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia

Blood2019-11-1316 citations